Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress.
The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate, described as a potent, orally active porcupine inhibitor being developed as a targeted therapy for cancers triggered by Wnt-ligand.
Anson talks through their plans in motion for the phase II study.